Skip to main content

Table 1 Results of surgery and stereotactic radiosurgery (SRS) for brain metastases

From: Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors

Reference

n (patients and lesions)

Prescribed dose (median; range [Gy])*

Median OS

1-year PFS (%)

Patchell et al. 1990 [1]

25/25

Surgery

9.5

80

Patchell et al. 1998 [2]

49/49

Surgery

11.0

82

Pirzkall et al. 1998 [3]

236/311

20; 10–30

5.5

89

Cho et al. 1998 [4]

73/136

17.5; 6–50

7.8

80

Kocher et al. 1998 [5]

106/157

20; 12–25

8.0

85

Sneed et al. 1999 [6]

62/118a

43/117b

18; 15–22

17.5; 15–22

11.3

11.1

80

86

Varlotto et al. 2003 [7]

137/208

16; 12–25

Not given

90

Andrews et al. 2004 [8]

164/269c

Not given; 15–24

6.5

82

Bhatnagar et al. 2006 [9]

205/4-18 lesions eachd

16; 12–20

8.0

71

  1. OS: overall survival in months; PFS: progression-free survival; ?: data not reported
  2. * Prescription isodose or point varied, some series included SRS plus WBRT
  3. a SRS only
  4. b SRS plus WBRT (no significant difference in OS and PFS between both groups)
  5. c SRS plus WBRT
  6. d SRS plus/minus WBRT